Visperterminen, Switzerland

Thomas Zeiter

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Lonza Ag. Active years: 2011.



Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Zeiter: Innovator in Peptide Cyclization

Introduction

Thomas Zeiter is a notable inventor based in Visperterminen, Switzerland. He has made significant contributions to the field of peptide chemistry, particularly through his innovative work on peptide cyclization. His expertise and dedication to research have led to the development of novel compounds that hold promise for various applications.

Latest Patents

Thomas Zeiter holds a patent for an innovative compound related to on-resin peptide cyclization. The patent describes a novel compound of formula I, which showcases his ability to create unique solutions in the realm of peptide synthesis. This patent highlights his commitment to advancing scientific knowledge and practical applications in the field.

Career Highlights

Thomas Zeiter is currently employed at Lonza AG, a leading global provider of integrated healthcare solutions. His role at Lonza AG allows him to collaborate with other experts in the field and contribute to groundbreaking research and development projects. His work has been instrumental in pushing the boundaries of peptide technology.

Collaborations

Throughout his career, Thomas has worked alongside talented colleagues, including Stéphane Varray and Oleg Werbitzky. These collaborations have fostered an environment of innovation and creativity, enabling the team to achieve remarkable advancements in their research endeavors.

Conclusion

In summary, Thomas Zeiter is a distinguished inventor whose work in peptide cyclization has led to significant advancements in the field. His contributions, particularly through his patent and collaboration with esteemed colleagues, underscore his impact on scientific research and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…